CY1118657T1 - 6((s)-1-{1-[5-(2-yδpoξy-aiθoξy)-πypiδin-2-yλo]-1η-πypazoλ-3-yλo}-aiθyλo)-3η-1,3-βενζοθειαζολ-2-ονη) ως ενας εξαρτωμενος απο tarp γ8 ανταγωνιστης υποδοχεα αμρα - Google Patents

6((s)-1-{1-[5-(2-yδpoξy-aiθoξy)-πypiδin-2-yλo]-1η-πypazoλ-3-yλo}-aiθyλo)-3η-1,3-βενζοθειαζολ-2-ονη) ως ενας εξαρτωμενος απο tarp γ8 ανταγωνιστης υποδοχεα αμρα

Info

Publication number
CY1118657T1
CY1118657T1 CY20171100252T CY171100252T CY1118657T1 CY 1118657 T1 CY1118657 T1 CY 1118657T1 CY 20171100252 T CY20171100252 T CY 20171100252T CY 171100252 T CY171100252 T CY 171100252T CY 1118657 T1 CY1118657 T1 CY 1118657T1
Authority
CY
Cyprus
Prior art keywords
ylo
tarp
ydpoxy
pypidin
pipazol
Prior art date
Application number
CY20171100252T
Other languages
Greek (el)
English (en)
Inventor
Jon Kevin Reel
Warren Jaye Porter
Jeffrey Michael Witkin
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1118657T1 publication Critical patent/CY1118657T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY20171100252T 2012-11-27 2017-02-24 6((s)-1-{1-[5-(2-yδpoξy-aiθoξy)-πypiδin-2-yλo]-1η-πypazoλ-3-yλo}-aiθyλo)-3η-1,3-βενζοθειαζολ-2-ονη) ως ενας εξαρτωμενος απο tarp γ8 ανταγωνιστης υποδοχεα αμρα CY1118657T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261730273P 2012-11-27 2012-11-27
PCT/US2013/070885 WO2014085153A1 (en) 2012-11-27 2013-11-20 6-((s)-1-{1-[5-(2-hydroxy-ethoxy)-pyridin-2-yl]-1h-pyrazol-3-yl}- ethyl)-3h-1,3-benzothiazol-2-one as a tarp-gamma 8 dependent ampa receptor antagonist

Publications (1)

Publication Number Publication Date
CY1118657T1 true CY1118657T1 (el) 2017-07-12

Family

ID=49753484

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100252T CY1118657T1 (el) 2012-11-27 2017-02-24 6((s)-1-{1-[5-(2-yδpoξy-aiθoξy)-πypiδin-2-yλo]-1η-πypazoλ-3-yλo}-aiθyλo)-3η-1,3-βενζοθειαζολ-2-ονη) ως ενας εξαρτωμενος απο tarp γ8 ανταγωνιστης υποδοχεα αμρα

Country Status (35)

Country Link
US (1) US8765960B2 (enExample)
EP (1) EP2925754B1 (enExample)
JP (1) JP6246227B2 (enExample)
KR (1) KR101693133B1 (enExample)
CN (1) CN104797578B (enExample)
AP (1) AP2015008489A0 (enExample)
AR (1) AR093527A1 (enExample)
AU (1) AU2013352594B2 (enExample)
BR (1) BR112015011200A2 (enExample)
CA (1) CA2889243C (enExample)
CL (1) CL2015001419A1 (enExample)
CR (1) CR20150267A (enExample)
CY (1) CY1118657T1 (enExample)
DK (1) DK2925754T3 (enExample)
DO (1) DOP2015000113A (enExample)
EA (1) EA026686B1 (enExample)
ES (1) ES2618260T3 (enExample)
HR (1) HRP20170274T1 (enExample)
HU (1) HUE033447T2 (enExample)
IL (1) IL238831B (enExample)
JO (1) JO3225B1 (enExample)
MA (1) MA38126B1 (enExample)
MX (1) MX356478B (enExample)
MY (1) MY177721A (enExample)
PE (1) PE20151728A1 (enExample)
PH (1) PH12015501154B1 (enExample)
PL (1) PL2925754T3 (enExample)
PT (1) PT2925754T (enExample)
SG (1) SG11201504164VA (enExample)
SI (1) SI2925754T1 (enExample)
TN (1) TN2015000200A1 (enExample)
TW (2) TW201825484A (enExample)
UA (1) UA114345C2 (enExample)
WO (1) WO2014085153A1 (enExample)
ZA (1) ZA201503733B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201609719A (zh) * 2014-05-28 2016-03-16 美國禮來大藥廠 作為TARP-γ8依賴性AMPA受體拮抗劑之6-經取代-3H-1,3-苯并噻唑-2-酮化合物
UY36654A (es) 2015-04-29 2016-10-31 Janssen Pharmaceutica Nv Azabenzimidazoles con propiedades moduladoras del receptor ampa y composiciones farmacéuticas que los contienen
CN107635970B (zh) * 2015-04-29 2021-03-12 詹森药业有限公司 苯并咪唑酮和苯并噻唑酮化合物以及它们作为ampa受体调节剂的用途
ES2759348T3 (es) 2015-04-29 2020-05-08 Janssen Pharmaceutica Nv Imidazopirazinas y pirazolopirimidinas y su utilización como moduladores de receptores AMPA
KR20170141769A (ko) 2015-04-29 2017-12-26 얀센 파마슈티카 엔.브이. 인돌론 화합물 및 ampa 수용체 조절제로서의 이의 용도
CA3039676A1 (en) * 2016-10-26 2018-05-03 Janssen Pharmaceutica Nv Fused bicylic pyridine compounds and their use as ampa receptor modulators
RU2650523C1 (ru) * 2017-07-24 2018-04-16 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Производное пиридоксина для лечения эпилепсии
RU2703286C1 (ru) * 2019-06-18 2019-10-16 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Соли (5-гидрокси-3,4-бис(гидроксиметил)-6-метилпиридин-2-ил)метансульфокислоты и способ их получения

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY132385A (en) * 1995-08-31 2007-10-31 Novartis Ag 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives
JP2000281676A (ja) * 1999-01-25 2000-10-10 Yamanouchi Pharmaceut Co Ltd Ampa拮抗化合物の新規製造法
CN1245386C (zh) * 2000-06-12 2006-03-15 卫材株式会社 1,2-二氢吡啶化合物及其制备方法和用途
US8995993B2 (en) * 2000-10-11 2015-03-31 Gogo Llc System for managing mobile internet protocol addresses in an airborne wireless cellular network
AU2005316313B2 (en) * 2004-12-17 2011-09-29 Eli Lilly And Company Novel MCH receptor antagonists
WO2007076161A2 (en) 2005-12-27 2007-07-05 Myriad Genetics, Inc Compounds with therapeutic activity
TW200817385A (en) * 2006-07-04 2008-04-16 Organon Nv Heterocyclic derivatives
CA2739559A1 (en) * 2008-10-08 2010-04-15 Pfizer Inc. Tetrahydrofuranyl sulfonamides and pharmaceutical compositions thereof
AU2010204118B2 (en) * 2009-01-12 2012-12-20 Icagen, Inc. Sulfonamide derivatives
AU2011261586B2 (en) * 2010-06-01 2015-08-27 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
WO2012137982A2 (en) * 2011-04-05 2012-10-11 Takeda Pharmaceutical Company Limited Sulfonamide derivative and use thereof
TW201609719A (zh) * 2014-05-28 2016-03-16 美國禮來大藥廠 作為TARP-γ8依賴性AMPA受體拮抗劑之6-經取代-3H-1,3-苯并噻唑-2-酮化合物

Also Published As

Publication number Publication date
SG11201504164VA (en) 2015-07-30
DK2925754T3 (en) 2017-02-20
AR093527A1 (es) 2015-06-10
TW201825484A (zh) 2018-07-16
MY177721A (en) 2020-09-23
HRP20170274T1 (hr) 2017-04-07
IL238831B (en) 2018-08-30
CN104797578A (zh) 2015-07-22
MA38126A1 (fr) 2017-03-31
KR20150070401A (ko) 2015-06-24
PT2925754T (pt) 2017-02-27
PH12015501154A1 (en) 2015-08-10
PH12015501154B1 (en) 2018-05-30
AU2013352594B2 (en) 2016-02-18
WO2014085153A1 (en) 2014-06-05
CL2015001419A1 (es) 2015-10-02
IL238831A0 (en) 2015-06-30
JO3225B1 (ar) 2018-03-08
PL2925754T3 (pl) 2017-07-31
CN104797578B (zh) 2016-11-23
CA2889243A1 (en) 2014-06-05
PE20151728A1 (es) 2015-12-02
HK1209116A1 (en) 2016-03-24
EA201590823A1 (ru) 2015-08-31
MX2015006697A (es) 2015-08-05
MA38126B1 (fr) 2017-11-30
ZA201503733B (en) 2017-09-27
TWI618705B (zh) 2018-03-21
US20140148441A1 (en) 2014-05-29
TW201434834A (zh) 2014-09-16
DOP2015000113A (es) 2015-06-15
US8765960B2 (en) 2014-07-01
TN2015000200A1 (en) 2016-10-03
BR112015011200A2 (pt) 2017-07-11
JP2016501219A (ja) 2016-01-18
AU2013352594A1 (en) 2015-06-04
EA026686B1 (ru) 2017-05-31
HUE033447T2 (en) 2017-11-28
WO2014085153A8 (en) 2014-07-31
CR20150267A (es) 2015-09-16
CA2889243C (en) 2017-06-13
KR101693133B1 (ko) 2017-01-04
SI2925754T1 (sl) 2017-02-28
JP6246227B2 (ja) 2017-12-13
EP2925754B1 (en) 2016-12-28
EP2925754A1 (en) 2015-10-07
ES2618260T3 (es) 2017-06-21
UA114345C2 (uk) 2017-05-25
MX356478B (es) 2018-05-30
AP2015008489A0 (en) 2015-05-31

Similar Documents

Publication Publication Date Title
CY1118657T1 (el) 6((s)-1-{1-[5-(2-yδpoξy-aiθoξy)-πypiδin-2-yλo]-1η-πypazoλ-3-yλo}-aiθyλo)-3η-1,3-βενζοθειαζολ-2-ονη) ως ενας εξαρτωμενος απο tarp γ8 ανταγωνιστης υποδοχεα αμρα
EA201591008A1 (ru) Пиридин-2-амиды, пригодные в качестве агонистов каннабиноидного рецептора 2
UA111640C2 (uk) ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
BR112015031903A8 (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto
MX388893B (es) Formulaciones de anticuerpos estables acuosas.
MX373916B (es) Composicion topica de ketoprofeno.
UA115357C2 (uk) Похідні піридин-4-ілу
UA116801C2 (uk) ПОХІДНІ ПІРОЛО[2,3-d]ПІРИМІДИНУ ЯК АГОНІСТИ РЕЦЕПТОРА CB2
WO2015056094A3 (en) Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent
EA201400822A1 (ru) Производные гетероциклических амидов в качестве антагонистов p2xрецептора
MX377170B (es) Composiciones de gel de brimonidina y metodos de uso.
UY34785A (es) Formulación en cápsulas solubilizadas de [(1s)-1-{[(2s,4r)-4-(7-cloro-4metoxiisoquinolin-1-iloxi)-2-({(1r,2s)-1-[(ciclopropilsulfonil)carbamoil]-2-etenilciclopropil}carbamoil)pirrolidin-1-il]carbonil}-2,2-dimetilpropil]carbamato de 1,1-dimetiletilo
GB201105050D0 (en) Pharmaceutical agent
UA116654C2 (uk) Похідні пурину як агоністи канабіноїдного рецептора св2
EA201790939A1 (ru) ТРИАЗОЛО[4,5-d]ПИРИМИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ КАННАБИНОИДНЫХ РЕЦЕПТОРОВ ТИПА 2
PH12016500865A1 (en) Composite formulation comprising tadalafil and amlodipine
WO2014146111A3 (en) Analgesic compounds and methods of use
WO2015013709A8 (en) Compositions for treating skin thickening
MX2014014579A (es) Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide.
EA201600123A1 (ru) Производные 1-(пиперазин-1-ил)-2-([1,2,4]триазол-1-ил)этанона
HK1212978A1 (zh) 芥子酸的新型衍生物
WO2013057579A3 (en) Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors
EA201400609A1 (ru) Твердые формы препаратов иматиниба, ресуспензируемые непосредственно перед применением
WO2015070231A8 (en) Multiple stream content presentation
MX385113B (es) Uso de hidróxido de potasio en el tratamiento de la queratosis actínica.